UK markets closed
NIKKEI 225
38,460.08 +907.92 (+2.42%) HANG SENG
17,201.27 +372.34 (+2.21%) CRUDE OIL
82.67 -0.69 (-0.83%) GOLD FUTURES
2,338.10 -4.00 (-0.17%) DOW
38,381.73 -121.96 (-0.32%) Bitcoin GBP
51,996.66 -1,637.52 (-3.05%)
Gilead Sciences, Inc. (GILD)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 12:57PM EDT. Market open.
| Previous close | 67.03 |
| Open | 66.59 |
| Bid | 66.95 x 100 |
| Ask | 66.99 x 300 |
| Day's range | 66.36 - 67.18 |
| 52-week range | 65.90 - 87.87 |
| Volume | |
| Avg. volume | 7,190,954 |
| Market cap | 83.485B |
| Beta (5Y monthly) | 0.20 |
| PE ratio (TTM) | 14.88 |
| EPS (TTM) | 4.50 |
| Earnings date | 25 Apr 2024 |
| Forward dividend & yield | 3.08 (4.59%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | 83.88 |
ZacksWhat's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.
ZacksIncyte (INCY) Earnings Expected to Grow: Should You Buy?
Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksGilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports first-quarter 2024 results.
© 2024 Yahoo. All rights reserved.